Glutamine, a nonessential amino acid, has recently received increasing attention because this amino acid becomes essential during stress and catabolic states, including BMT. In fact glutamine seems to modulate immune function, to promote faster intestinal healing and to have trophic effects on the intestine. We designed two randomized clinical trials to evaluate the role of glutamine-enriched parenteral nutrition (GEPN) in patients affected by haematological malignancies submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation (aPBSCT) or immunoselected CD34+aPBSCT. In the first randomized study, group 1A (12 pts, 7m/5f, median age 37.5y) received Glamin (Fresenius Kabi) 1000 ml/die (a parenteral aminoacidic solution also containing glutamine 20 g) from day +1 after aPBSCT, while group 1B (15 pts, 10m/5f, median age 47y) received a placebo. In the second randomized study, group 2A (10 pts, 5m/5f, median age 31.5y) received Dipeptiven (Fresenius Kabi) 100 ml/die (a parenteral solution containing only glutamine 13.46 g) from day +1 after aPBSCT, while group 2B (11 pts, 8m/3f, median age 49y) received a placebo. Both study groups were comparable for age, sex, diagnosis, conditioning regimen and CD34+/kg cell dose reinfused. There were no significant differences in PMN, platelets, Reticulocyte recovery, length of hospitalization and non-prophylactic antibiotic therapy, fever, sepsis occurrence, transfusional requirements. Statistical analysis showed a difference in lymphocytes recovery: in first study lymphocytes counts >0.5x10e9/L was achieved on day 16,5 (range 10-27) in patients receiving Glamin and on day 29 (range 12-50) in patients receiving placebo, p=0.005; in second study lymphocytes counts >0.5x10e9/L was achieved on day 18 (range 12-22) in patients receiving Dipeptiven and on day 29 (range 12-60) in patients receiving placebo, p=0.009. These differences are maintained when CD4+ subset was analyzed separately. Furthermore all patients undergone GEPN (1A and 2A groups), compared to all patients undergone placebo (1B and 2B groups), showed a significant decrease in mucositis severity peak calculated by DMS (daily mucositis score: sum of signs's and symptoms's daily score) (p=0.025). Thus, in our experience, GEPN is safe and efficacious to improve lymphocytes recovery and, particularly, CD4+ subset, after aPBSCT; further studies are needed to assess clinical benefits of such approach to justify economical impact.
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Characterization of minor histocompatibility antigens on canine hematopoietic precursor cells M. Weber, C. Lange, M. Franz, E. Kremmer, H. Kolb (Munich, D) Minor histocompatibility antigens (mHA) are mainly defined by the following characteristics: they are recognized by T cells, their presentation is restricted to a specific MHC type, they occur with variable phenotype frequencies and they are segregated in a Mendelian fashion. Here we report the in vitro immunization of T cells against mHA in DLA-identical canine littermates and the subsequent characterization of the resulting CTLs. Bone marrow derived dendritic cells were used for the generation of mHA-specific CTLs using co-culture with fresh donor T cells. The ability of immunized CTLs to suppress the growth of hematopoietic precursor cells (HPC) was tested in a Delta-Assay, performed in analogy of the delta culture in the mouse (Muench MO and Moore MA, 1992) using lineage-negative bone marrow as target cells. The target cells were plated in a 96-well plate at decreasing cell numbers ranging from 16.000 to 125 cells per well. The growth of HPC was stimulated by the addition of 20% FCS, 100 ng/ml SCF, 800 U/ml GM-CSF, 2 U/ml Epo, 100 ng/ml IL-3 and 3% allogeneic MLC supernatant. At the start of the Delta Assay irradiated mHA-specific CTLs were added to the wells in a fixed number of 10.000 cells, resulting in a range of effector to target cell ratios from 0.6:1 to 80:1. After 4 days the 3H-thymidine uptake of the target cells was measured and compared to the control. The results showed a highly specific inhibition of HPC-growth in 53% (8/15) analysed DLA-identical littermate combinations, ranging from a HPC-growth inhibition of 30% to 98% compared to the control. In vitro segregation analysis performed in one selected family showed that mHA-specific CTLs were able to recognize HPC from some but not all littermates of the family apart from the stimulator (table 1) whereas HPC from an unrelated animal were not recognized. We further observed one way reactivity in two cases in different dog families. One setting between two male littermates proved the involvement of autosomally-encoded mHA. The other case was showing a one-way reaction of female-derived CTLs against male HPC, strongly indicating the involvement of a Y -chromosome encoded mHA. We have shown an in vitro immunization of CTLs against mHA in DLA-identical canine littermates and shown the heredity of the involved mHA through segregation analysis in one canine family. These mHA in the dog may prove as a valid model for the treatment of leukemia in man by mHA-specific T cells.
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Generation of surviving-specific cytotoxic T-Lymphocytes for the treatment of hematological malignancies M. Zeis, S. Siegel, A. Wagner, P. Dreger, N. Schmitz (Kiel, D) Survivin is a member of the family of inhibitor of apoptosis proteins and is overexpressed in many types of cancer including hematopoietic malignancies. Recently, Survivin-derived peptides were shown to induce CD8+ cytotoxic T lymphocytes (CTL) when presented on dendritic cells (DC). In the current study, we determined whether Survivin-reactive CTL were able to recognize and to kill Survivin-expriming hematological targets. Survivinspecific CTL were generated from leukaphereses products obtained from healthy HLA-A*0201 positive volunteers by incubating T cells with autologous dendritic cells pulsed with DOTAP complexed Survivin-RNA. Survivin-specific CTL lysed HLA-A2+ Survivin + tumor cells including primary lymphoma, acute lymphatic leukemia, multiple myeloma, as well as fresh leukemic blasts from AML patients, indicating that Survivin-derived peptides are naturally processed and presented by tumors. Normal Survivin-negative target cells including CD14+ monocytes and activated B cells were not attacked by Survivin-specific CTL. For the first time, these data show that Survivin-specific CTL are capable of lysing both tumor cell lines and fresh leukemic blasts and thus can be used for specific cellular immunotherapy against several hematological malignancies. Einsele, A.L. Bissinger, G. Rauser, C. Sinzger, F. Frank, H. Hebart, G. Jahn (Tuebingen, D) Adoptive transfer of donor-derived human cytomegalovirus (HCMV)-specific cytotoxic T -lymphocytes (CTLs) can restore protective immunity after stem cell transplantation (SCT). Different strategies to generate HCMV-specific CTLs have been described, using either HCMV-infected antigen-presenting cells (APCs) or protein-/peptid-pulsed APCs with limits in application. In this report we demonstrate a different strategy to isolate HCMV-specific CTLs within hours, using magnetic enrichment of cytokine (IFNgamma) secreting cells. 1 -5x104 HCMV-specific CTLs were isolated from buffy coats (100 ml, 1 -1,5x108 PBMNCs) of 5 different healthy, HLA-A*0201 HCMV-seropositive blood donors using the IFN-gamma secretion assay following stimulation with the HLA-A2 restricted HCMVpp65 peptide NLVPMVATV. After 3 and 6 weeks of ex vivo expansion with IL2 and autologous or allogeneic feeder cells >1 x 107 and > 1 x 109 HCVM-specific T cells, respectively could be obtained. 82% (range 54.7 -99.3%) of these isolated and in vitro expanded cells stained positive with MHC/peptide tetrameric complexes and 78% (32.2% -99.5%) showed HCMVpp65 peptide-specific IFN-gamma secretion. 75% (range 55.3 -88.0%) of these cells produced perforin and >50% specific killing of peptide-pulsed T2-cells as well as HLA-A*0201-positive HCMV-infected fibroblasts was detected (E:T ratio 20:1 and 40:1). Auto-and alloreactivity could be excluded using autologous and allogeneic skin fibroblasts as target cells. Thus, the approach with the IFN-gamma secretion assay allows to isolate HCMV-specific CTLs which can be expanded sufficiently for clinical application after SCT. In upscaling of the technique and using for selection leukapheresis products, the technique will allow to isolate up to > 107 HCMV-specific T cells sufficient for adoptive T cell therapy without further ex vivo expansion. Chronic Myelogenous Leukaemia (CML), characterised by the presence of Philadelphia chromosome (Ph) is the result of the t(9;22) translocation, w hich encodes for the bcr-abl fusion oncogene. The b3a2 junctional region peptides therefore represent potential immunogenic antigens. K562 is a Ph+, HLA class I negative cell line, which expresses b3a2 bcr-abl mRNA. These cells were transfected with single HLA-A*03011 or HLA-B*08011 alleles by electroporation. Acid elution of CML specific peptides from HLA-A3 or HLA-B8 K562 transfectants as well as from HLA-A3 (b3a2 +) CML patients, was performed. The resultant peptides were analysed by mass spectrometry with nanospray ionisation. Sequencing results obtained confirmed the presence of the HLA-A*03011 restricted peptide KQSSKALQR on both transfected K562 and primary CML cells. Tetramers of HLA-A3 and HLA-B8 with the corresponding eluted peptides were produced. These are currently being used to detect antigenspecific CTLs from HLA-A3 and HLA-B8 patients at various stages of their disease and treatment. These data demonstrate that (1) CML cells do express HLA-associated leukaemia-specific peptides and that (2) CML patients have circulating CTLs specific for the b3a2 fusion peptides. (3)That these cells can be expanded with specific peptides in vitro. These findings provide encouragement for an eventual immunotherapeutic approach for the treatment of CML by in vitro stimulation of patients T cells against specific leukaemic peptides providing the basis for immunotherapeutic intervention in CML.
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Clinical scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells (DC) for vaccination -a phase I trial
J. Babatz, C. Röllig, G. Moeneclay, G. Ehninger, M. Schmitz, M. Bornhäuser (Dresden, Bergisch Gladbach, D)
Objectives: The aim of this study was to test the performance of the CliniMACS platform to select large numbers of CD14+ monocytes. In a second step varying doses of DC generated out of the CD14+ positive fraction were administered either fresh or after thawing in 3 different parenteral routes. Material and methods: Standard apheresis was performed in 6 patients with metastatic solid carcinoma. The mononuclear cell preparation was stored at 4 C° overnight. Labeling of cells with CD14+ microbeads and loading on the column according to the standard CliniMACS procedure. The positive fraction was then harvested and cultured for 8 days in medium supplemented with 1% pretested AB serum, GMP grade GM-CSF (1000 IU/ml), IL-4 (1000 IU/ml). Immature DC were either cryopreserved in aliquots or differentiated into mature DC by culture with TNF-alpha (1100 IU/ml), prostaglandin E2(1 µg/ml), IL-6 (1000 IU/ml), IL-1 beta (1900 IU/ml), IL-4 (1000 IU/ml) and GM-CSF (1000 IU/ml) for 3 days. For consecutive applications immature DC were thawed and differentiation was induced as described above. The quality of the cells was tested by microscopy, dye exclusion, annexin staining and expression of CD83, HLA-DR and CD80/86 by FACS. The capacity to stimulate allogeneic and autologous T cells was tested using thymidine incorporation. All patients received 1x10e7 DC i.v., 1x10e6 DC subcutaneously (s.c.) and intradermally (i.d.) at the same day on 3 occasions every two weeks (one fresh, two thawed preparations). Results: The median number of CD14+ monocytes recovered in the positive fraction after immunomagnetic selection was 3.24 x 10e9 (range (r ), 1.9-4.7) with a yield of 87.6 %(r, 63.9-100.0) and a median purity of 97.0 % (r, 94.9-99.0). The median percentage of CD83+ DC after 10 days of culture was 80 % (r, 59.5-89.8) leading to an overall yield of 9.8 % (r, 6.7-15.7) for the whole procedure. Allo-and autostimulatory capacity could be shown for all DC preparations by thymidine incorporation. T cell stimulation was significantly reduced in thawed samples. No grade 2 -4 toxicities were documented after DC administration. Conclusion: Clinical scale immunomagnetic CD14+ selection using the CliniMACS procedure leads to a pure preparation of monocytes which can be used to generate DC. Fresh and thawed DC obtained by a standard culture method are functionally active in-vitro and can be safely infused i.v. or injected s.c./i.d.
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Dendritic cell vaccination of multiple myeloma patients before and after autologous transplantation S. Auffermann-Gretzinger, K.E. Stockerl-Goldstein, C.J. Benike, B. Taidi, A. Liso, R. Rajapaksa, A. van Beckhoven, E.G. Engleman, K.G. Blume, R. Levy (Stanford, USA) Cellular immunotherapies are a promissing and attractive treatment option for malignant diseases. Idiotype (Id)-based vaccination of multiple myeloma patients has been shown to be feasable and well tolerated, but Id-specifc immune responses are rarely achieved. We therefore investigated a new vaccination strategy administering dendritic cell vaccines prior to and after autologus hematopoietic cell transplantation (AHCT). The regimen consisted of one Id-KLH (Keyhole Limpet Protein) pulsed dendritic cell (DC) vaccination before stem cell collection. Six month after transplantation the patients received the second i.v. infusion of DC pulsed with Id-KLH and 5 subcutaneous boosts of Id-KLH and GM-CSF. Id proteins were purified from patients sera collected prior to chemotherapy. DC were isolated freshly from apheresis product and matured in vitro during Id-KLH pulsing for 36 hours. 21 patients have been included in this trial. 11 patients went off study before having received half of the vaccines. Out of the remaining 10 patients 9 have completed the series. 9 out of these 10 patients generated an idiotype-specific proliferative immune response and all 10 patients attained a KLH-specific response. We also measured the cytokines TNF-a, IFN-g, IL-2, IL-4, IL-5, IL-10 secreted by PBMC after stimulation with Idiotype and KLH and detected mainly TH1 type immune responses. In 2 patients tested we detected idiotype specific cytotoxic T cells. The high rate of induced idiotype-specific immune responses of patients completing our new vaccination schema seems to favor this approach of vaccination. We conclude that vaccination with Id-KLH prior to and after AHCT can induce Id specific cellular responses with a high efficiency.
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CMV and EBV-specific CTL expanded with dendritic cells is skewed towards functional effector phenotype F. Chen, R. Duarte, L. Barber, P. Travers, A. Dodi, A. Madrigal (London, UK) Severe infective complications including CMV infection and EBVassociated post-transplant lymphoma arise following SCT as a result of deficient T-cell reconstitution. Ex-vivo expansion of viral epitope-specific CD8+ cytotoxic T -cells for adoptive immunotherapy may confer long-term antigen-specific immunity whilst avoiding GVHD. However considerable functional and phenotypic heterogeneity exists among antigen-specific cells both in healthy individuals and after SCT and we have characterised this heterogeneity in EBV and CMV-specific CTL generated with dendritic cells. We used peptide-pulsed DC to generate thirteen lines of autologous EBV and CMV-specific CTL's. DC's were established from PBMC in FCS free media with GMCSF and IL-4, matured with TNF-a and Poly-IC and pulsed with HLA-A2 and HLA-B8 restricted peptides from CMV-pp65 (NLV), EBV-EBNA3C (FLR) and EBV-LMP2a (CLG). After co-culturing with positively selected CD8+ T -cells, flow cytometric analysis with HLA-tetramers showed that tetramer positive cells for NLV, FLR and CLG expanded up to 50%, 75% and 80% of CD8+ cells respectively. The tetramer staining CD8+ T cells were further characterised with anti-CCR7 and anti-CD45RA antibodies which define four sub-populations corresponding to naïve, central or long-standing memory, effector memory and terminally differentiated effector cells. Most of the in-vitro expanded tetramer positive cells were of CCR7-phenotype, corresponding to effector CD8+ T cells with a mean of 60% in the CCR7-/CD45RA-compartment and 40% in the CCR7-/CD45RA+ compartment. This is in contrast to findings in healthy donors and SCT patients where C D45RA-CMVspecific cells account for 30 to 40% of tetramer positive cells. Intracellular studies of our CTL lines demonstrated high levels of function with expression of perforin, granzyme A and interferon gamma. The high proportion of CCR7-/CD45RA-CTL's suggests that despite the high specificity and functionality of in-vitro DCgenerated cells, they may not contribute to the memory pool of expandable long-lasting cells with important implications for CTLimmunotherapy trials.
O156
The frequency of cytotoxic CD8+ effector-cells with specifictity against the Wilm's tumor gene encoded transcription factor (WT1) antigen after allogeneic stem cell transplantation for CML: evidence for their involvement in tumor clearance U. Hilbers, G. Hartung, T. Lange, D. Niederwieser, L. Uharek (Leipzig, D) The malignant transformation of immature CD34 progenitor cells in pts with CML is associated with elevated expression of WT1 and it has been demonstrated that WT1 can serve as a target for cytotoxic T lymphocytes (CTL). Therefore, we have investigated the frequency of HLA-A0201-restricted CTLs specific for WT1 in patients with CML before and after allogeneic stem cell transplanatation. PBMCs were stimulated with the WT1 peptides RMFPNAPYL (aa 126-134) and SLGEQQYSV (aa 187-195) and the frequency of peptide-specific CTLs was determined by Elispotanalysis of interferon-secreting responder cells. An HIV-specific peptide was used as negative control. In patients with high numbers of WT1 specific cells, the responding cells were purified by the interferon-secretion assay (Miltenyi Biotec) and further characterized with regard to their immunologic phenotype. None of 5 controls and none of 9 pts with CML showed WT-1-specific CTLs before transplantation. However, in 4 of 8 pts WT1-specific cells were detected in high frequency (up to 211:100.000) up to 465 days after transplantation. In all positive pts, the CTLresponse started very early (ca. day 30) and was directed against both WT-1 peptides, indicating that multiple epitopes w ere involved. The response was either temporary or long-lasting. In 2 pts who had become bcr/abl negative very rapidly, the CTLresponse diminished after day 50. Separation of the responding cells revealed that they were predominantly of CD8+ effector cell type (Cd27-/CD45RA+/CD57+). Despite high numbers of WT-1-specific CTLs, all patients showed regular engraftment. Thus our findings support previous in vitro data indicating that colony formation by normal CD34 progenitor cells is unaffected by WT-1 reactive cells. According to our data the tissue specific transcription factor WT1 could be an ideal target for antigenspecific therapy of CML and other WT1-expressing malignancies.
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In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation T. Kurokawa, K. Fischer, H. Bertz, J. Finke, A. Mackensen (Freiburg, Regensburg, D) It has been shown that after allogeneic peripheral blood stem cell transplantation (PBSCT) donor T cells can induce potent graftversus-tumor (GVT) effects in hematologic malignancies and possibly solid tumors such as renal cell carcinoma. Two patients (27 and 30 years old) with metastatic melanoma received allogeneic PBSCT from an HLA-identical sibling donor after reduced conditioning with fludarabine, carmustine, and melphalan. One patient showed a delayed mixed response with complete regression of lymph node metastases but persistent liver metastasis at day +60 and +120 consistent with a GVT response. In order to generate donor-derived tumor-reactive cytotoxic T lymphocytes (CTL), peripheral blood mononuclear cells were stimulated with donor monocyte-derived dendritic cells (DC) loaded with host tumor lysate. We have shown previously, that two weekly stimulation cycles with tumor-loaded DC followed by restimulation with irradiated tumor cells alone were optimal for induction of tumor-specific CTL responses in vitro. Using these
